Article Text

Download PDFPDF
Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors
  1. Marcus Säemann1,2,
  2. Andreas Kronbichler3
  1. 1 6th Medical Department, Nephrology and Dialysis, Clinic Ottakring, Vienna, Austria
  2. 2 Medical School, Sigmund Freud University, Vienna, Austria
  3. 3 Department of Medicine, University of Cambridge, Cambridge, UK
  1. Correspondence to Dr Marcus Säemann, 6th Medical Department, Nephrology and Dialysis, Clinic Ottakring, Vienna 1160, Austria; SAEMANNMARCUS{at}GMAIL.COM


Sodium–glucose cotransporter- 2 inhibitors (SGLT- 2i) have recently been demonstrated to exert profound cardio- and nephroprotection in large cardiovascular outcome trials. They reduce progression of chronic kidney disease (CKD) including albuminuria and improve outcomes in heart failure patients with and without type 2 diabetes on top of angiotensin-blocking agents. These benefits translate into improved mortality in cardiorenal risk patients. While the detailed molecular mechanisms underlying these surprising clinical outcomes are not fully understood, their antidiabetic properties are not causative. Rather reduction of glomerular hyperfiltration and tubuloprotection are involved as root cause mechanisms of their clinical effects. Finally, their side effect profile is advantageous especially in non-diabetic patients also reducing the risk of acute kidney injury. Among the independent risk factors for excess mortality, CKD is still one of the strongest predictors of a poor prognosis in patients with both ANCA- associated vasculitis (AAV) and lupus nephritis (LN). Since patients with autoimmune disease were excluded from all recent large renal outcome trials with SGLT-2i and given their strong nephroprotective potential, we herein advocate to study this unique class of disease-modifying therapies when it comes to kidney and cardiovascular health in patients with AAV and LN.

  • lupus nephritis
  • hypertension
  • lupus erythematosus
  • systemic

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Handling editor Josef S Smolen

  • Contributors MS drafted the first version of the manuscript. AK revised the manuscript and approved the final version.

  • Competing interests MS has received honoraria for consulting and lectures from Astra Zeneca, Bayer, Boehringer-Ingelheim, Novartis, Otsuka and Vifor Pharma. AK has received research grants from Otsuka and Vifor Pharma, honoraria for lectures from TerumoBCT and Vifor Pharma and consulting fees from UriSalt and Catalyst Biosciences.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Commissioned; externally peer reviewed.